Pharmaceutical

BNT-325 by Duality Biologics (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer.

Jul 6, 2024 - 04:00
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

Next Article

Hexagonal perovskite oxides: Electrolytes for next-generation protonic ceramic f...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Merck sues U.S. to halt Medicare drug-price negotiation; FDA oncology head wants advisory panels to keep voting on new drugs

STAT+: Pharmalittle: Merck sues U.S. to halt Medicare d...

Jun 6, 2023

Opinion: STAT readers on burnt-out infectious disease doctors, 12-month prescriptions, and counting disabled Americans

Opinion: STAT readers on burnt-out infectious disease d...

Dec 3, 2023

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (...

Jul 6, 2024